title: The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation.
authors.affiliation: Institute of Clinical Research, University of Montpellier, 641, avenue Doyen-Giraud, 34093 Montpellier cedex 5, France. Electronic address: louis.monnier@inserm.fr.
authors.forename: L
authors.initials: L
authors.lastname: Monnier
authors.affiliation: Diabetes Research Group, Swansea University, United Kingdom.
authors.forename: D R
authors.initials: DR
authors.lastname: Owens
authors.affiliation: Department of Medicine, Perugia University School of Medicine, Perugia, Italy.
authors.forename: G B
authors.initials: GB
authors.lastname: Bolli
mesh_terms: D003920:Diabetes Mellitus / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D000069036:Insulin Glargine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D000069036:Insulin Glargine
keywords: Accumulation risk; New long-acting insulins; Pharmacodynamics